HIGH TIDE INC (HITI) Stock Fundamental Analysis
NASDAQ:HITI - CA42981E4013 - Common Stock
3.6 USD
+0.11 (+3.15%)
3.56 USD
-0.04 (-1.11%)
Overall HITI gets a fundamental rating of 4 out of 10. We evaluated HITI against 193 industry peers in the Pharmaceuticals industry. HITI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HITI has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
In the past year HITI had a positive cash flow from operations.
HITI had negative earnings in each of the past 5 years.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of HITI (-4.17%) is better than 72.54% of its industry peers.
HITI's Return On Equity of -6.91% is fine compared to the rest of the industry. HITI outperforms 76.68% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.21%, HITI belongs to the top of the industry, outperforming 81.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROIC | 5.21% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 2.22%, HITI is in the better half of the industry, outperforming 78.24% of the companies in the same industry.
Looking at the Gross Margin, with a value of 25.83%, HITI is in line with its industry, outperforming 52.85% of the companies in the same industry.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
HITI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, HITI has more shares outstanding
The number of shares outstanding for HITI has been increased compared to 5 years ago.
HITI has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.98 indicates that HITI is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.98, HITI is in the better half of the industry, outperforming 76.17% of the companies in the same industry.
HITI has a debt to FCF ratio of 4.52. This is a neutral value as HITI would need 4.52 years to pay back of all of its debts.
HITI's Debt to FCF ratio of 4.52 is amongst the best of the industry. HITI outperforms 83.94% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that HITI is not too dependend on debt financing.
HITI has a Debt to Equity ratio (0.30) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 3.98 |
ROIC/WACC0.58
WACC9.05%
2.3 Liquidity
A Current Ratio of 1.57 indicates that HITI should not have too much problems paying its short term obligations.
The Current ratio of HITI (1.57) is worse than 65.80% of its industry peers.
A Quick Ratio of 0.97 indicates that HITI may have some problems paying its short term obligations.
HITI's Quick ratio of 0.97 is on the low side compared to the rest of the industry. HITI is outperformed by 74.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The earnings per share for HITI have decreased strongly by -1957.14% in the last year.
Looking at the last year, HITI shows a quite strong growth in Revenue. The Revenue has grown by 9.22% in the last year.
HITI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.59% yearly.
EPS 1Y (TTM)-1957.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1233.33%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%10.9%
3.2 Future
The Earnings Per Share is expected to grow by 74.44% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 15.05% on average over the next years. This is quite good.
EPS Next Y-6.88%
EPS Next 2Y83.38%
EPS Next 3Y93.9%
EPS Next 5Y74.44%
Revenue Next Year11.73%
Revenue Next 2Y16.73%
Revenue Next 3Y17.75%
Revenue Next 5Y15.05%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
HITI is valuated quite expensively with a Price/Forward Earnings ratio of 58.05.
Based on the Price/Forward Earnings ratio, HITI is valued a bit cheaper than the industry average as 67.88% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.80. HITI is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 58.05 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HITI indicates a rather cheap valuation: HITI is cheaper than 84.97% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, HITI is valued cheaply inside the industry as 80.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.85 | ||
| EV/EBITDA | 12.03 |
4.3 Compensation for Growth
HITI's earnings are expected to grow with 93.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y83.38%
EPS Next 3Y93.9%
5. Dividend
5.1 Amount
HITI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.6
+0.11 (+3.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners7.98%
Inst Owner Change-4.1%
Ins Owners8.81%
Ins Owner ChangeN/A
Market Cap292.32M
Analysts80
Price Target5.73 (59.17%)
Short Float %5.24%
Short Ratio9.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.69%
Min EPS beat(2)-11.37%
Max EPS beat(2)-8%
EPS beat(4)1
Avg EPS beat(4)-48.88%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)5
Avg EPS beat(8)27.56%
EPS beat(12)9
Avg EPS beat(12)32.7%
EPS beat(16)11
Avg EPS beat(16)20.33%
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.6%
Revenue beat(4)3
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.9%
Revenue beat(8)5
Avg Revenue beat(8)0.38%
Revenue beat(12)9
Avg Revenue beat(12)1.89%
Revenue beat(16)13
Avg Revenue beat(16)7.54%
PT rev (1m)9.98%
PT rev (3m)12.71%
EPS NQ rev (1m)40.01%
EPS NQ rev (3m)57.14%
EPS NY rev (1m)-21.22%
EPS NY rev (3m)-21.22%
Revenue NQ rev (1m)-0.93%
Revenue NQ rev (3m)-0.3%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)-0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 58.05 | ||
| P/S | 0.74 | ||
| P/FCF | 28.85 | ||
| P/OCF | 16.32 | ||
| P/B | 2.89 | ||
| P/tB | 8.18 | ||
| EV/EBITDA | 12.03 |
EPS(TTM)-0.09
EYN/A
EPS(NY)0.06
Fwd EY1.72%
FCF(TTM)0.12
FCFY3.47%
OCF(TTM)0.22
OCFY6.13%
SpS4.89
BVpS1.25
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROCE | 6.6% | ||
| ROIC | 5.21% | ||
| ROICexc | 6.43% | ||
| ROICexgc | 16.26% | ||
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 2.55% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 1.22 | ||
| Cap/Depr | 47.33% | ||
| Cap/Sales | 1.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 70.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 3.98 |
F-Score5
WACC9.05%
ROIC/WACC0.58
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1957.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1233.33%
EPS Next Y-6.88%
EPS Next 2Y83.38%
EPS Next 3Y93.9%
EPS Next 5Y74.44%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%10.9%
Revenue Next Year11.73%
Revenue Next 2Y16.73%
Revenue Next 3Y17.75%
Revenue Next 5Y15.05%
EBIT growth 1Y37.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year316.17%
EBIT Next 3Y105.72%
EBIT Next 5Y77.37%
FCF growth 1Y182.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.28%
OCF growth 3YN/A
OCF growth 5YN/A